X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with Abbott India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs ABBOTT INDIA - Comparison Results

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA ABBOTT INDIA NATCO PHARMA/
ABBOTT INDIA
 
P/E (TTM) x 16.1 39.6 40.8% View Chart
P/BV x 17.4 10.2 170.8% View Chart
Dividend Yield % 0.7 0.7 97.0%  

Financials

 NATCO PHARMA   ABBOTT INDIA
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
ABBOTT INDIA
Mar-18
NATCO PHARMA/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs8776,110 14.4%   
Low Rs4243,996 10.6%   
Sales per share (Unadj.) Rs223.41,552.2 14.4%  
Earnings per share (Unadj.) Rs31.1188.8 16.5%  
Cash flow per share (Unadj.) Rs40.3196.4 20.5%  
Dividends per share (Unadj.) Rs5.0055.00 9.1%  
Dividend yield (eoy) %0.81.1 70.6%  
Book value per share (Unadj.) Rs219.5796.6 27.6%  
Shares outstanding (eoy) m33.0721.25 155.6%   
Bonus/Rights/Conversions PA--  
Price / Sales ratio x2.93.3 89.4%   
Avg P/E ratio x20.926.8 78.2%  
P/CF ratio (eoy) x16.125.7 62.8%  
Price / Book Value ratio x3.06.3 46.7%  
Dividend payout %16.129.1 55.2%   
Avg Mkt Cap Rs m21,504107,376 20.0%   
No. of employees `000NA3.3 0.0%   
Total wages/salary Rs m1,1283,937 28.6%   
Avg. sales/employee Rs ThNM9,929.3-  
Avg. wages/employee Rs ThNM1,185.1-  
Avg. net profit/employee Rs ThNM1,207.7-  
INCOME DATA
Net Sales Rs m7,38932,985 22.4%  
Other income Rs m1671,170 14.3%   
Total revenues Rs m7,55634,155 22.1%   
Gross profit Rs m1,7935,245 34.2%  
Depreciation Rs m304162 188.0%   
Interest Rs m36638 958.6%   
Profit before tax Rs m1,2906,215 20.8%   
Minority Interest Rs m460-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3092,203 14.0%   
Profit after tax Rs m1,0274,012 25.6%  
Gross profit margin %24.315.9 152.6%  
Effective tax rate %23.935.4 67.5%   
Net profit margin %13.912.2 114.3%  
BALANCE SHEET DATA
Current assets Rs m3,68122,655 16.2%   
Current liabilities Rs m3,1236,681 46.7%   
Net working cap to sales %7.648.4 15.6%  
Current ratio x1.23.4 34.8%  
Inventory Days Days8965 138.1%  
Debtors Days Days5929 201.3%  
Net fixed assets Rs m7,685835 919.9%   
Share capital Rs m331213 155.6%   
"Free" reserves Rs m6,67016,715 39.9%   
Net worth Rs m7,25916,928 42.9%   
Long term debt Rs m9550-   
Total assets Rs m11,95724,162 49.5%  
Interest coverage x4.5163.7 2.8%   
Debt to equity ratio x0.10-  
Sales to assets ratio x0.61.4 45.3%   
Return on assets %11.716.8 69.5%  
Return on equity %14.223.7 59.7%  
Return on capital %20.736.9 56.1%  
Exports to sales %39.40-   
Imports to sales %5.70-   
Exports (fob) Rs m2,908NA-   
Imports (cif) Rs m421NA-   
Fx inflow Rs m3,445369 934.9%   
Fx outflow Rs m7033,807 18.5%   
Net fx Rs m2,743-3,438 -79.8%   
CASH FLOW
From Operations Rs m1,4401,527 94.3%  
From Investments Rs m-1,089-2,148 50.7%  
From Financial Activity Rs m-353-1,024 34.4%  
Net Cashflow Rs m-1-1,646 0.1%  

Share Holding

Indian Promoters % 52.0 0.0 -  
Foreign collaborators % 1.5 75.0 2.0%  
Indian inst/Mut Fund % 7.8 7.9 99.2%  
FIIs % 16.6 0.1 16,630.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 17.1 152.0%  
Shareholders   25,395 18,270 139.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   ELDER PHARMA  FDC LTD.  SUN PHARMA  STRIDES SHASUN LTD  TTK HEALTHCARE  

Compare NATCO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Sell-Off; Sensex Slumps Over 530 Points(Closing)

Share markets in India continued their sell-off seen during the last week and ended the day deep in the red. All sectoral indices traded on a negative note.

Related Views on News

VINATI ORG. Plunges by 5%; BSE 500 Index Down 1.7% (Market Updates)

Sep 24, 2018 | Updated on Sep 24, 2018

VINATI ORG. share price has plunged by 5% and its current market price is Rs 1,364. The BSE 500 is down by 1.7%. The top gainers in the BSE 500 Index are TCS (up 3.9%) and CYIENT LTD (up 3.8%). The top losers are VINATI ORG. (down 5.5%) and ABBOTT INDIA (down 5.2%).

WOCKHARDT LTD. Plunges by 5%; BSE HEALTHCARE Index Down 1.9% (Market Updates)

Sep 24, 2018 | Updated on Sep 24, 2018

WOCKHARDT LTD. share price has plunged by 5% and its current market price is Rs 588. The BSE HEALTHCARE is down by 1.9%. The top gainers in the BSE HEALTHCARE Index are BLISS GVS PHARMA (up 1.0%) and THYROCARE TECHNOLOGIES (up 1.0%). The top losers are WOCKHARDT LTD. (down 5.0%) and PFIZER (down 6.1%).

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Sep 24, 2018 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 5-YR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS